Meg Elias

TL;DR: Patients with refractory large B‐cell lymphoma who received CAR T‐cell therapy with axi‐cel had high levels of durable response, with a safety profile that included myelosuppression, the cytokine release syndrome, and neurologic events.

TL;DR: This regimen of KTE-C19 was safe for further study in phase 2 and induced durable remissions in patients with refractory DLBCL and demonstrated peak expansion within 2 weeks and continued to be detectable at 12+ months in patientswith ongoing CR.

TL;DR: Early use of tocilizumab may reduce the incidence of severe CRS but not NE in patients treated with CAR T cell therapy, and data provide evidence that the underlying pathophysiology of NE may differ from that of CRS.

TL;DR: The first multicenter trial of anti-CD19 chimeric antigen receptor (CAR) T cells in refractory, aggressive NHL met the primary endpoint of objective response rate (ORR) and key secondary endpoints include duration of response, frequency of adverse events (AEs), and levels of CAR T cells and serum cytokines.

TL;DR: Results from the interim analysis of ZUMA‐1, the 1st multicenter trial of an anti‐CD19 chimeric antigen receptor T cell, axi‐cel, in refractory aggressive NHL, showed an objective response rate (ORR) of 79% (complete response [CR] 52%; Blood2016;128:LBA‐6).